Comparing the Costs and Diagnostic Outcomes of Replacing Cytology with the QIAsure DNA Methylation Test as a Triage within HPV Primary Cervical Cancer Screening in The Netherlands

Detecting hypermethylation of tumour suppressor genes could provide an alternative to liquid-based cytology (LBC) triage within HPV primary cervical screening. The impact of using the QIAsure® FAM19A4/mir124-2 DNA Methylation Test (QIAGEN, N.V, Hilden, Germany) on CIN3+ diagnoses, retention, unnecessary colposcopies, and programme costs is unknown. A decision-tree model was developed to compare LBC with the QIAsure Methylation testing to guide colposcopy referral. Incorporating clinician- and self-sampling pathways the model was informed by the Dutch cervical cancer screening programme, publis... Mehr ...

Verfasser: Puri Sudhir, Krishnan
Kagenaar, Eva
Meijer, Michelle
Hesselink, Albertus T.
Adams, Elisabeth
Turner, Katy M. E.
Huntington, Susie
Dokumenttyp: Artikel
Erscheinungsdatum: 2023
Reihe/Periodikum: Puri Sudhir , K , Kagenaar , E , Meijer , M , Hesselink , A T , Adams , E , Turner , K M E & Huntington , S 2023 , ' Comparing the Costs and Diagnostic Outcomes of Replacing Cytology with the QIAsure DNA Methylation Test as a Triage within HPV Primary Cervical Cancer Screening in The Netherlands ' , Diagnostics (Basel, Switzerland) , vol. 13 , no. 24 , 3612 . https://doi.org/10.3390/diagnostics13243612
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-27623129
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://research.vumc.nl/en/publications/0684839f-364b-4028-abc0-ff8cb4268607